Skip to main content
SpringerLink
Log in

Immunogenicity of Therapeutic Proteins

  • Chapter
  • First Online:
Pharmaceutical Biotechnology

  • 555 Accesses

Abstract

The use of proteins for medical applications has revolutionized therapies of many diseases/disorders that were often incurable with small-molecule medicines. However, since the first use of proteins as medicines, their immunogenicity has been a major problem. Over the years, the quality and safety of therapeutic protein products have improved dramatically. Nevertheless, even the protein medicines of the newest generation may still cause adverse immunological events, posing a safety risk for patients and/or compromising their efficacy. Immunogenicity of therapeutic proteins is a complex, multifactorial phenomenon. In this chapter, we summarize the current knowledge about immune mechanisms underlying the immunogenicity of therapeutic proteins and discuss influencing factors and clinical consequences of protein immunogenicity as well as strategies for immunogenicity assessment and mitigation.

Sadly, Wim Jiskoot passed away by the time of publication of this sixth edition.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 89.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Aledort L (1994) Inhibitors in hemophilia patients: current status and management. Am J Hematol 47:208–217

    Article  CAS  PubMed  Google Scholar 

  • Antonelli G, Dianzani F (1999) Development of antibodies to interferon beta in patients: technical and biological aspects. Eur Cytokine Netw 10:413–422

    CAS  PubMed  Google Scholar 

  • Bachmann MF, Rohrer UH, Kündig TM, Bürki K, Hengartner H, Zinkernagel RM (1993) The influence of antigen organization on B cell responsiveness. Science 262:1448–1451

    Article  CAS  PubMed  Google Scholar 

  • Barbosa MD, Vielmetter J, Chu S, Smith DD, Jacinto J (2006) Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicity. Clin Immunol 118:42–50

    Article  CAS  PubMed  Google Scholar 

  • Barnard JG, Babcock K, Carpenter JF (2013) Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity. J Pharm Sci 102:915–928

    Article  CAS  PubMed  Google Scholar 

  • Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305:1460–1468

    Article  CAS  PubMed  Google Scholar 

  • Bertolotto A, Deisenhammer F, Gallo P, Sölberg SP (2004) Immunogenicity of interferon beta: differences among products. J Neurol 251:II15-II24

    Article  PubMed  Google Scholar 

  • Billiet T, Vande Casteele N, Van Stappen T, Princen F, Singh S, Gils A, Ferrante M, Van Assche G, Cleynen I, Vermeire S (2015) Immunogenicity to infliximab is associated with HLA-DRB1. Gut 64:1344–1345

    Article  CAS  PubMed  Google Scholar 

  • Bloem K, van Leeuwen A, Verbeek G, Nurmohamed MT, Wolbink GJ, van der Kleij D, Rispens T (2015) Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods 418:29–38

    Article  CAS  PubMed  Google Scholar 

  • Brandse JF, Mathôt RA, van der Kleij D, Rispens T, Ashruf Y, Jansen JM, Rietdijk S, Löwenberg M, Ponsioen CY, Singh S, van den Brink GR, D'Haens GR (2016) Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 14:251–258

    Article  CAS  PubMed  Google Scholar 

  • Brinks V, Weinbuch D, Baker M, Dean Y, Stas P, Kostense S, Rup B, Jiskoot W (2013) Preclinical models used for immunogenicity prediction of therapeutic proteins. Pharm Res 30:1719–1728

    Article  CAS  PubMed  Google Scholar 

  • Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469–475

    Article  CAS  PubMed  Google Scholar 

  • Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med 358:1109–1117

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cousens L, Najafian N, Martin WD, De Groot AS (2014) Tregitope: immunomodulation powerhouse. Hum Immunol 75:1139–1146

    Article  CAS  PubMed  Google Scholar 

  • de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL, Fernandes LG, Tamashiro WM, Simioni PU (2015) Inflammatory bowel disease: an overview of immune mechanisms and biological treatments. Mediat Inflamm 2015:1–11

    Article  Google Scholar 

  • Deegan PB (2012) Fabry disease, enzyme replacement therapy and the significance of antibody responses. J Inherit Metab Dis 35:227–243

    Article  CAS  PubMed  Google Scholar 

  • Ehlinger C, Spear N, Doddareddy R, Shankar G, Schantz A (2019) A generic method for the detection of polyethylene glycol specific IgG and IgM antibodies in human serum. J Immunol Methods 474:112669

    Article  CAS  PubMed  Google Scholar 

  • Fakharzadeh SS, Kazazian HH Jr (2000) Correlation between factor VIII genotype and inhibitor development in hemophilia a. Semin Thromb Hemost 26:167–172

    Article  CAS  PubMed  Google Scholar 

  • Fijal B, Ricci D, Vercammen E, Palmer PA, Fotiou F, Fife D, Lindholm A, Broderick E, Francke S, Wu X, Colaianne J, Cohen N (2008) Case–control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia. Pharmacogenomics 9:157–167

    Article  CAS  PubMed  Google Scholar 

  • Finco D, Baltrukonis D, Clements-Egan A, Delaria K, Gunn GR 3rd, Lowe J, Maia M, Wong T (2011) Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics. J Pharm Biomed Anal 54:351–358

    Article  CAS  PubMed  Google Scholar 

  • Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS (2007) Immunological responses to exogenous insulin. Endocr Rev 28:625–652

    Article  CAS  PubMed  Google Scholar 

  • Food and Drug Administration (2002) Adalimumab. 2002. Pharmacology reviews: adalimumab product approval information—licensing action. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125057s110TOC.cfm. Accessed on 4 Nov 2017

  • Gorovits B, Clements-Egan A, Birchler M, Liang M, Myler H, Peng K, Purushothama S, Rajadhyaksha M, Salazar-Fontana L, Sung C, Xue L (2016) Pre-existing antibody: biotherapeutic modality-based review. AAPS J 18:311–320

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Griswold KE, Bailey-Kellogg C (2016) Design and engineering of deimmunized biotherapeutics. Curr Opin Struct Biol 39:79–88

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hamuro L, Kijanka G, Kinderman F, Kropshofer H, Bu DX, Zepeda M, Jawa V (2017) Perspectives on subcutaneous route of administration as an immunogenicity risk factor for therapeutic proteins. J Pharm Sci 106:2946–2954

    Article  CAS  PubMed  Google Scholar 

  • Han PD, Cohen RD (2004) Managing immunogenic responses to infliximab: treatment implications for patients with Crohn’s disease. Drugs 64:1767–1777

    Article  CAS  PubMed  Google Scholar 

  • Harding FA, Stickler MM, Razo J, DuBridge RB (2010) The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2:256–265

    Article  PubMed  PubMed Central  Google Scholar 

  • Hausl C, Ahmad RU, Sasgary M, Doering CB, Lollar P, Richter G, Schwarz HP, Turecek PL, Reipert BM (2005) High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood 106:3415–3422

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W (2004) Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21:897–903

    Article  CAS  PubMed  Google Scholar 

  • Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS (2013) T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin Immunol 149:534–555

    Article  CAS  PubMed  Google Scholar 

  • Jiskoot W, Kijanka G, Randolph TW, Carpenter JF, Koulov AV, Mahler HC, Joubert MK, Jawa V, Narhi LO (2016) Mouse models for assessing protein immunogenicity: lessons and challenges. J Pharm Sci 105:1567–1575

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kijanka G, Jiskoot W, Sauerborn M, Schellekens H, Brinks V (2012) Immunogenicity of 12 therapeutic proteins. In: Hovgaard L, Frokjaer S, van de Weert M (eds) Pharmaceutical formulation development of peptides and proteins. CRC Press, Boca Raton, FL, pp 297–322

    Google Scholar 

  • Krishna M, Palme H, Duo J, Lin Z, Corbett M, Dodge R, Piccoli S, Myler H, Pillutla R, Desilva B (2015) Development and characterization of antibody reagents to assess anti-PEG IgG antibodies in clinical samples. Bioanalysis 7:1869–1883

    Article  CAS  PubMed  Google Scholar 

  • Li C, Desai AK, Gupta P, Dempsey K, Bhambhani V, Hopkin RJ, Ficicioglu C, Tanpaiboon P, Craigen WJ, Rosenberg AS, Kishnani PS (2021) Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction. Genet Med 23:845–855

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lipsky PE, Calabrese LJ, Kavanaugh A, Sundy JS, Wright D, Wolfson M, Becker MA (2014) Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther 16:R60

    Article  PubMed  PubMed Central  Google Scholar 

  • Liu L (2015) Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and fc-fusion proteins. J Pharm Sci 104:1866–1884

    Article  CAS  PubMed  Google Scholar 

  • Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P (1999) Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354:1932–1939

    Article  CAS  PubMed  Google Scholar 

  • Malucchi S, Bertolotto A. (2008) Clinical aspects of immunogenicity to biopharmaceuticals. In: Weert MV, Møller EH. Immunogenicity of biopharmaceuticals Springer, New York, NY; 47: 27–56

    Chapter  Google Scholar 

  • Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ, Taniguchi G, Wierda D, Zuckerman LA (2004) Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 289:1–16

    Article  CAS  PubMed  Google Scholar 

  • Moore WV, Leppert P (1980) Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 51:691–697

    Article  CAS  PubMed  Google Scholar 

  • Moss AC, Brinks V, Carpenter JF (2013) Review article: Immunogenicity of anti-TNF biologics in IBD–the role of patient, product and prescriber factors. Aliment Pharmacol Ther 38:1188–1197

    Article  CAS  PubMed  Google Scholar 

  • Oldenburg J, Lacroix-Desmazes S, Lillicrap D (2015) Alloantibodies to therapeutic factor VIII in hemophilia a: the role of von Willebrand factor in regulating factor VIII immunogenicity. Haematologica 100:149–156

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Perini P, Facchinetti A, Bulian P, Massaro AR, Pascalis DD, Bertolotto A, Biasi G, Gallo P (2001) Interferon-Beta (INF-Beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 12:56–61

    CAS  PubMed  Google Scholar 

  • Praditpornsilpa K, Kupatawintu P, Mongkonsritagoon W, Supasyndh O, Jootar S, Intarakumthornchai T, Pongskul C, Prasithsirikul W, Achavanuntakul B, Ruangkarnchanasetr P, Laohavinij S, Eiam-Ong S (2009) The association of anti-R-HuEpo-associated pure red cell aplasia with HLA-DRB1*09-DQB1*0309. Nephrol Dial Transplant 24:1545–1549

    Article  CAS  PubMed  Google Scholar 

  • Prümmer O (1997) Treatment-induced antibodies to interleukin-2. Biotherapy 10:15–24

    Article  PubMed  Google Scholar 

  • Richter WF, Bhansali SG, Morris ME (2012) Mechanistic determinants of biotherapeutics absorption following sc administration. AAPS J 14:559–570

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ross C, Clemmesen KM, Svenson M, Sørensen PS, Koch-Henriksen N, Skovgaard GL, Bendtzen K (2000) Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 48:706–712

    Article  CAS  PubMed  Google Scholar 

  • Rougeot C, Marchand PM, Dray F, Girard F, Job JC, Pierson M, Ponte C, Rochiccioli P, Rappaport R (1991) Comparative study of biosynthetic human growth hormone immunogenicity in growth hormone deficient children. Horm Res 35:76–81

    Article  CAS  PubMed  Google Scholar 

  • Ryff JC (1997) Clinical investigation of the immunogenicity of interferon-alpha 2a. J Interf Cytokine Res 17:S29–S33

    CAS  Google Scholar 

  • Schellekens H (2002a) Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1:457–462

    Article  CAS  PubMed  Google Scholar 

  • Schellekens H (2002b) Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24:1720–1740

    Article  CAS  PubMed  Google Scholar 

  • Schellekens H, Casadevall N (2004) Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 251:II4–II9

    Article  PubMed  Google Scholar 

  • Schellekens H, Jiskoot W (2006) Erythropoietin-associated PRCA: still an unsolved mystery. J Immunotoxicol 3:123–130

    Article  CAS  PubMed  Google Scholar 

  • Schellekens H, Hennink WE, Brinks V (2013) The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res 30:1729–1734

    Article  CAS  PubMed  Google Scholar 

  • Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, Fiscella M, Gorovits B, Kirschner S, Moxness M, Parish T, Quarmby V, Smith H, Smith W, Zuckerman LA, Koren E (2008) Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 48:1267–1281

    Article  CAS  PubMed  Google Scholar 

  • Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, Quarmby V, Richards S, Schneider CK, Subramanyam M, Swanson S, Verthelyi D, Yim S (2014) Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides—harmonized terminology and tactical recommendations. AAPS J 16:658–673

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Singh SK (2011) Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 100:354–387

    Article  CAS  PubMed  Google Scholar 

  • van Beers MM, Jiskoot W, Schellekens H (2010) On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. J Interf Cytokine Res 30:767–775

    Article  Google Scholar 

  • van de Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, Vermeire S (2013) Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 108:962–971

    Article  CAS  Google Scholar 

  • van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T (2015a) The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 74:311–314

    Article  PubMed  Google Scholar 

  • van Schie KA, Wolbink GJ, Rispens T (2015b) Cross-reactive and pre-existing antibodies to therapeutic antibodies–effects on treatment and immunogenicity. MAbs 7:662–671

    Article  PubMed  PubMed Central  Google Scholar 

  • van Schie KA, Kruithof S, van Schouwenburg PA, Vennegoor A, Killestein J, Wolbink G, Rispens T (2017) Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: the immune response to antibody therapeutics preferentially targets the antigen-binding site. J Allergy Clin Immunol 139:1035–1037

    Article  PubMed  Google Scholar 

  • van Schouwenburg PA, Rispens T, Wolbink GJ (2013a) Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 9:164–172

    Article  PubMed  Google Scholar 

  • van Schouwenburg PA, Krieckaert CL, Rispens T, Aarden L, Wolbink GJ, Wouters D (2013b) Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis 72:1680–1686

    Article  PubMed  Google Scholar 

  • Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C (2013) Antidrug antibodies (ADA) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 72:165–178

    Article  CAS  PubMed  Google Scholar 

  • Weigle WO (1971) Recent observations and concepts in immunological unresponsiveness and autoimmunity. Clin Exp Immunol 9:437–447

    CAS  PubMed  PubMed Central  Google Scholar 

  • Xue L, Rup B (2013) Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics. AAPS J 15:893–896

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Further Reading

  • Brinks V, Jiskoot W, Schellekens H (2011) Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res 28:2379–2385

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ducret A, Ackaert C, Bessa J, Bunce C, Hickling T, Jawa V, Kroenke MA, Lamberth K, Manin A, Penny HL, Smith N, Terszowski G, Tourdot S, Spindeldreher S (2011) Assay format diversity in pre-clinical immunogenicity risk assessment: toward a possible harmonization of antigenicity assays. MAbs 14:1993522

    Article  Google Scholar 

  • Filipe V, Hawe A, Schellekens H, Jiskoot W (2010) Aggregation and immunogenicity of therapeutic proteins, in aggregation of therapeutic proteins. Wiley, Hoboken, NJ

    Google Scholar 

  • Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W (2007) Immunogenicity of therapeutic proteins. In: Gad SC (ed) Handbook of pharmaceutical biotechnology. Wiley, Hoboken, NJ, pp 911–931

    Google Scholar 

  • Moussa EM, Panchal JP, Moorthy BS, Blum JS, Joubert MK, Narhi LO, Topp EM (2016) Immunogenicity of therapeutic protein aggregates. J Pharm Sci 105:417–430

    Article  CAS  PubMed  Google Scholar 

  • Schellekens H (2010) The immunogenicity of therapeutic proteins. Discov Med 9:560–564

    PubMed  Google Scholar 

  • Schellekens H, Crommelin D, Jiskoot W (2007) Immunogenicity of antibody therapeutics. In: Dübel S (ed) Handbook of therapeutic antibodies. Wiley, Weinheim, pp 267–276

    Chapter  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands

    Theo Rispens

  2. Leiden Academic Center for Drug Research (LACDR), Leiden University, Leiden, The Netherlands

    Wim Jiskoot

  3. Division of BioTherapeutics, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands

    Grzegorz Kijanka

Authors
  1. Theo Rispens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wim Jiskoot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Grzegorz Kijanka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Theo Rispens .

Editor information

Editors and Affiliations

  1. Utrecht University, Utrecht, The Netherlands

    Daan J. A. Crommelin

  2. Faculty of Pharmaceutical Sciences, The University of British Columbia (UBC), Vancouver, BC, Canada

    Robert D. Sindelar

  3. College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA

    Bernd Meibohm

Rights and permissions

Reprints and permissions

Copyright information

© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rispens, T., Jiskoot, W., Kijanka, G. (2024). Immunogenicity of Therapeutic Proteins. In: Crommelin, D.J.A., Sindelar, R.D., Meibohm, B. (eds) Pharmaceutical Biotechnology. Springer, Cham. https://doi.org/10.1007/978-3-031-30023-3_7

Download citation

Publish with us

Policies and ethics

Search

Navigation